Abstract
Purpose
The goal of this study was to estimate pre- and post-gadolinium-enhanced high-spatial resolution susceptibility-weighted imaging (SWI) in patients with brain neoplasms.
Materials and methods
A total of 17 patients (8 women, 9 men) with brain neoplasms participated in this study. In addition to conventional magnetic resonance imaging, pre- and post-gadolinium-enhanced SWI was performed. The contrast-to-noise ratio (CNR) and major diameters of the brain tumor were measured for quantitative analyses, and intratumoral susceptibility signal intensity (ITSS) was graded for semiquantitative analysis.
Results
Both bright and dark enhancement were observed at the pathological lesion on postcontrast SWI. Some postcontrast SWI results suggested leakage of contrast material due to breakdown of the blood-brain barrier. There were no statistical differences (Student’s t-test) between postcontrast SWI and three-dimensional (3D) T1-weighted images regarding the major diameters of the brain tumors. CNR of postcontrast 3D T1-weighted images was statistically superior to that of postcontrast SW images (P < 0.01, Wilcoxon signed-rank test). Malignant tumors tended to have a higher ITSS score.
Conclusion
SWI clearly visualized the architecture of brain neoplasms. This imaging technique may be useful for evaluating tumor characterization in clinical use.
Article PDF
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
References
Haacke EM, Xu Y, Cheng YC, Reichenbach JR. Susceptibility weighted imaging (SWI). Magn Reson Med 2004;52:612–618.
Rauscher A, Sedlacik J, Barth M, Haacke EM, Reichenbach JR. Noninvasive assessment of vascular architecture and function during modulated blood oxygenation using susceptibility weighted magnetic resonance imaging. Magn Reson Med 2005;54:87–95.
Rauscher A, Sedlacik J, Barth M, Mentzel HJ, Reichenbach JR. Magnetic susceptibility-weighted MR phase imaging of the human brain. AJNR Am J Neuroradiol 2005;26:736–742.
Sehgal V, Delproposto Z, Haacke EM, Tong KA, Wycliffe N, Kido DK, et al. Clinical applications of neuroimaging with susceptibility-weighted imaging. J Magn Reson Imaging 2005;22:439–450.
Sehgal V, Delproposto Z, Haddar D, Haacke EM, Sloan AE, Zamorano LJ, et al. Susceptibility-weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses. J Magn Reson Imaging 2006;24:41–51.
Pinker K, Noebauer-Huhmann IM, Stavrou I, Hoeftberger R, Szomolanyi P, Karanikas G, et al. High-resolution contrastenhanced, susceptibility-weighted MR imaging at 3T in patients with brain tumors: correlation with positron-emission tomography and histopathologic findings. AJNR Am J Neuroradiol 2007;2:1280–1286.
Pinker K, Noebauer-Huhmann IM, Stavrou I, Hoeftberger R, Szomolanyi P, Karanikas G, et al. High-field, high-resolution, susceptibility-weighted magnetic resonance imaging: improved image quality by addition of contrast agent and higher field strength in patients with brain tumors. Neuroradiology 2008;50:9–16.
Park MJ, Kim HS, Jahng GH, Ryu CW, Park SM, Kim SY. Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibility-weighted imaging in patients with gliomas: comparison with MR perfusion imaging. AJNR Am J Neuroradiol 2009;30:1402–1408.
Lin W, Mukherjee P, An H, Yu Y, Wang Y, Vo K, et al. Improving high-resolution MR bold venographic imaging using a T1 reducing contrast agent. J Magn Reson Imaging 1999;10:118–123.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Hori, M., Ishigame, K., Kabasawa, H. et al. Precontrast and postcontrast susceptibility-weighted imaging in the assessment of intracranial brain neoplasms at 1.5 T. Jpn J Radiol 28, 299–304 (2010). https://doi.org/10.1007/s11604-010-0427-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11604-010-0427-z